Panel votes down heart safety claim for naproxen

Federal health experts say that new research is not strong enough to conclude that naproxen, the pain reliever in Aleve and many other medications, is safer on the heart than rival drugs used by millions of Americans to treat aches and pains.

The Food and Drug Administration advisory panel voted 16-9 against the conclusion that naproxen has a lower risk of and stroke compared with similar anti-inflammatory medications like ibuprofen, sold as Advil and in other generic formulations.

Debate about whether one drug in the class is safer than others has waged for more than a decade without a clear answer.

The FDA convened the meeting this week to consider new analyses that apparently show lower heart risks for . But panelists said the data was not conclusive.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pain reliever naproxen shows anti-viral activity against flu

Mar 21, 2013

The over-the-counter anti-inflammatory drug naproxen may also exhibit antiviral activity against influenza A virus, according to a team of French scientists. The finding, the result of a structure-based investigation, is ...

Red flags on pain reliever safety

Jul 19, 2011

For many people, pain relievers are wonder drugs, allowing them to carry on with their lives despite disabling arthritis, for instance, or recurrent headaches. But all pain relievers, whether sold over-the counter (OTC) or ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments